{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:22:24Z","timestamp":1780730544745,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41390-024-03341-x","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T10:01:47Z","timestamp":1718445707000},"page":"160-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute myeloid leukemia stem cell signature gene EMP1 is not an eligible therapeutic target"],"prefix":"10.1038","volume":"97","author":[{"given":"Laurens","family":"Van Camp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Depreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilke","family":"De Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Hofmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala\u00efka","family":"Van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Terras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Chantrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Dedeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Uyttebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"3341_CR1","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan, C. M. et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J. Clin. Oncol. 33, 2949\u20132962 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3341_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche, M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32, 2167\u20132177 (2018).","journal-title":"Leukemia"},{"key":"3341_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.19.01086","volume":"38","author":"KW Maloney","year":"2020","unstructured":"Maloney, K. W. et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of children\u2019s oncology group trial AALL0331. J. Clin. Oncol. 38, 602\u2013612 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3341_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353\u2013366 (2023).","journal-title":"Haematologica"},{"key":"3341_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/s41390-020-01199-3","volume":"89","author":"B Depreter","year":"2021","unstructured":"Depreter, B. et al. Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach. Pediatr. Res. 89, 1695\u20131705 (2021).","journal-title":"Pediatr. Res."},{"key":"3341_CR6","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig, U. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120, 3187\u20133205 (2012).","journal-title":"Blood"},{"key":"3341_CR7","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.3324\/haematol.2014.116574","volume":"100","author":"V Barlogis","year":"2015","unstructured":"Barlogis, V. et al. Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. Haematologica 100, e186\u2013e189 (2015).","journal-title":"Haematologica"},{"key":"3341_CR8","doi-asserted-by":"publisher","first-page":"28824","DOI":"10.1074\/jbc.270.48.28824","volume":"270","author":"V Taylor","year":"1995","unstructured":"Taylor, V., Welcher, A. A., Program, A. E. & Suter, U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J. Biol. Chem. 270, 28824\u201328833 (1995).","journal-title":"J. Biol. Chem."},{"key":"3341_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SWK Ng","year":"2016","unstructured":"Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"3341_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7150\/jca.35382","volume":"11","author":"S-Y Lin","year":"2020","unstructured":"Lin, S.-Y. et al. A 6-membrane protein gene score for prognostic prediction of cytogenetically normal acute myeloid leukemia in multiple cohorts. J. Cancer 11, 251\u2013259 (2020).","journal-title":"J. Cancer"},{"key":"3341_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","volume":"111","author":"BJ Lange","year":"2008","unstructured":"Lange, B. J. et al. Outcomes in CCG-2961, a children\u2019s oncology group phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Blood 111, 1044\u20131053 (2008).","journal-title":"Blood"},{"key":"3341_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis, A. S. et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s oncology group trial AAML0531. J. Clin. Oncol. 32, 3021\u20133032 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3341_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1200\/JCO.21.01612","volume":"40","author":"JA Pollard","year":"2022","unstructured":"Pollard, J. A. et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the children\u2019s oncology group protocol AAML1031. J. Clin. Oncol. 40, 2023\u20132035 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3341_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc, R. et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group. Haematologica 105, 1879\u20131886 (2020).","journal-title":"Haematologica"},{"key":"3341_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2010.029660","volume":"96","author":"BV Balgobind","year":"2011","unstructured":"Balgobind, B. V. et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96, 221\u2013230 (2011).","journal-title":"Haematologica"},{"key":"3341_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-022-00321-x","volume":"11","author":"N Zhang","year":"2022","unstructured":"Zhang, N. et al. Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers. Exp. Hematol. Oncol. 11, 69 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"3341_CR17","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/leu.2014.80","volume":"28","author":"IM Ari\u00ebs","year":"2014","unstructured":"Ari\u00ebs, I. M. et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia 28, 1828\u20131837 (2014).","journal-title":"Leukemia"},{"key":"3341_CR18","doi-asserted-by":"publisher","first-page":"17142","DOI":"10.1002\/jcb.28974","volume":"120","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD4. J. Cell. Biochem. 120, 17142\u201317150 (2019).","journal-title":"J. Cell. Biochem."},{"key":"3341_CR19","doi-asserted-by":"publisher","first-page":"e0138782","DOI":"10.1371\/journal.pone.0138782","volume":"10","author":"C-H Hsu","year":"2015","unstructured":"Hsu, C.-H. et al. Transcriptome profiling of pediatric core binding factor AML. PloS One 10, e0138782 (2015).","journal-title":"PloS One"},{"key":"3341_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2141.2006.06310.x","volume":"135","author":"H Ichikawa","year":"2006","unstructured":"Ichikawa, H. et al. Common gene expression signatures in t(8;21)-and inv(16)-acute myeloid leukaemia. Br. J. Haematol. 135, 336\u2013347 (2006).","journal-title":"Br. J. Haematol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03341-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03341-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03341-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:06:57Z","timestamp":1738753617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-024-03341-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1038\/s41390-024-03341-x","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare to have no potential conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Ethics Committee of the University Hospital of Ghent (EC2015-1443 1 April 2016 and EC2019-0294 20 March 2020). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent Statement"}}]}}